Partnerships

Track record of delivering clinical assets through collaborative partnerships

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.

Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.

Our experienced team learned their craft at Ablynx, Bicycle Therapeutics, Roche and other leading biopharma.

Partnerships